Next-generation Sequencing Data Analysis Market Growth & Trends
The global next-generation sequencing data analysis market is expected to reach USD 4,556.9 million by 2030, registering a CAGR of 22.89% over the forecast period, according to a new report by Grand View Research, Inc. The growth can be attributed to a significant decline in the cost of NGS installation in clinical diagnosis. Furthermore, the accessibility of genomic and proteomic data is anticipated to create significant growth opportunities. In addition, a reduction in the cost of sequencing is anticipated to boost the adoption rate of NGS, which would further drive the industry. The availability of tools, such as the Targeted Methyl-Seq platform and Agilent’s HaloPlex capture system from EpiGentek Group Inc. has aided in the DNA methylation profiles determination in individual genomes. The COVID-19 pandemic has enhanced NGS usage and has created a huge demand.
The NGS tools can generate a significant amount of data for scientists to analyze and study pathogenesis. Researchers from industry, academia, and government have used data analysis technology to help in understanding the characteristics, phylogenetics, and processes of SARS-CoV2. NGS technologies have helped to unveil biological information that has not been studied yet using conventional technologies. For instance, NGS has helped study genomic patterns associated with various biological processes and epigenomics. However, issues related to accessing storage management, and analysis of data are anticipated to offer huge R&D prospects, thus, driving the industry growth. Researchers that use high-throughput sequencers demand software systems, such as Laboratory Information Management Systems (LIMS) to archive and handle sequencing information.
Furthermore, the introduction of workflow management system solutions, such as Galaxy and Chipster, drives demand for technological advancements in data storage and management. Demand for technologically advanced infrastructure to monitor the flow of data analysis process from data generation to preliminary analysis to higher-level analysis has increased. Moreover, NGS data analysis tools are being constantly upgraded for obtaining effective results and higher utility. For instance, in December 2021, Bionano Genomics launched BioDiscovery’s NxClinical Software Version 6.1 for genome analysis. The version enables enhanced visualization and interpretation of NGS data for cancer and genetic disease domains. Such developments are anticipated to drive the industry over the forecast period.
Request a free sample copy or view the report summary: Next-generation Sequencing Data Analysis Market Report
Next-generation Sequencing Data Analysis Market Report Highlights
The services product segment dominated the industry in 2022. NGS has several advantages, in terms of speed and affordability, and many research institutes are unable to adopt it due to a lack of skilled professionals and sufficient computational infrastructure
The tertiary analysis workflow segment captured the major revenue share in 2022 as it accounts for the complex and important step of NGS, which is linked with the interpretation of the results
The in-house mode segment dominated the market in 2022 and is anticipated to remain dominant in the coming years. However, the outsourced mode segment is anticipated to witness the fastest growth rate from 2023 to 2030 owing to time and cost advantages
The short-read sequencing segment held the maximum share in 2022 due to the high adoption of short-read sequencing techniques and their cost-effective nature & ability to work with DNA fragments and the availability of several tools & algorithms
The academic research end-use segment dominated the market in 2022. A reduction in the NGS technology cost has fueled the NGS software platforms usage by several research centers & academic institutions for their research that require data interpretation
North America captured the highest revenue share in 2022 owing to the presence of well-developed information technology companies, favorable reimbursement network, and high government funding and high public & private expenditures in the biotechnology sector
Comentários